CAT No: CP26689
CAS No:201152-47-8
Synonyms/Alias:BOC-PHG-OSU;201152-47-8;SCHEMBL2484525;ZINC2556559;6438AH;FT-0643876;K-5879
Boc-Phg-OSu is a Boc-protected amino acid N-hydroxysuccinimide ester derivative of phenylglycine, designed for efficient amide-bond formation in peptide and bioconjugation workflows. The Boc group provides an N-protected amino functionality that can be carried through synthesis steps, while the OSu leaving group enables coupling under standard peptide-chemistry conditions. This reagent format is commonly used by peptide synthesis and chemical biology teams to introduce a phenylglycine residue or to convert amine-containing partners into stable amide-linked products.
1. Peptide Coupling Building Block
Boc-Phg-OSu is used as an activated phenylglycine coupling reagent for assembling peptide segments where amide bond formation is the key step. In custom peptide synthesis and medicinal chemistry programs, researchers rely on the OSu activation to promote efficient coupling with amine-containing nucleophiles, supporting rapid construction of peptide intermediates and analog libraries. The Boc-protected amino functionality helps maintain compatibility with protected-peptide strategies, allowing the phenylglycine unit to be incorporated while keeping the N-terminus protected for subsequent elongation.
2. Amide-Linkage Bioconjugation
Boc-Phg-OSu is frequently selected for chemical biology and bioconjugation workflows that require installing a phenylglycine-derived amide linkage onto an amine-bearing partner. Researchers use OSu-activated amino acid esters to couple to primary amines on peptides, linkers, or other functional biomolecular constructs, enabling controlled formation of stable amide connections for downstream characterization. This reagent format is particularly useful when the coupling partner is provided as a protected or partially protected amine-containing intermediate, and the workflow benefits from an activated ester rather than relying on less reactive carboxylic acid forms.
3. Peptidomimetic Intermediate Synthesis
Boc-Phg-OSu supports the preparation of peptidomimetic building blocks and medicinal chemistry intermediates that incorporate phenylglycine motifs via amide formation. In pharmaceutical intermediate development, chemists use activated amino acid derivatives to streamline the conversion of amine nucleophiles into amide-linked structures that can be further transformed into larger scaffolds. The combination of a protected amino terminus (Boc) with an OSu leaving group makes the reagent well suited for stepwise synthesis where the phenylglycine unit needs to be introduced cleanly as a defined amide component.
4. Solid-Phase Segment Preparation
Boc-Phg-OSu is applied in workflows that generate protected peptide segments prior to or during solid-phase assembly, where activated amino acid coupling reagents improve the efficiency of segment condensation. Peptide chemists preparing difficult sequences or analog panels often prefer activated ester formats to reduce coupling inefficiency when introducing specific residues such as phenylglycine. The reagent's Boc protection pattern aligns with protected-building-block strategies used to maintain control over functional group reactivity across multi-step peptide synthesis campaigns.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.